Clinical Trials on Dermatologic in New Zealand

Total 2776 results

Malaghan Institute of Medical Research

Recruiting

Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies (THERMAL)

Lymphoma | Leukemia | Myeloma | Temperature Change, Body | Haematological Malignancy

New Zealand
University of Sydney
University of Roma La Sapienza; Australasian Bone Marrow Transplant Recipient... and other collaborators

Recruiting

Prophylactic Early PN in HPT/BMT

Hematologic Neoplasms

Australia, New Zealand
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Australia, New Zealand
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Apellis Pharmaceuticals, Inc.

Completed

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. (PADDOCK)

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Thailand, New Zealand, Malaysia
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, New Zealand, Korea, Republic of, Italy
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, New Zealand
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
Takeda
Affymax

Completed

Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.

Anemia

United States, New Zealand, Australia, Italy, United Kingdom
Pfizer

Terminated

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Hemophilia A

United States, New Zealand
Protalex, Inc.

Terminated

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Idiopathic Thrombocytopenic Purpura (ITP)

Australia, New Zealand
Celgene

No longer available

Expanded Access for CC-2001

Other | Dermatologic

United States
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Ra Pharmaceuticals

Completed

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Australia, Canada, Denmark, Finland, Germany, Hungary, New Zealand
NYU Langone Health

Active, not recruiting

A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT

Hematologic Malignancy

United States
Memorial Sloan Kettering Cancer Center

Completed

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Hematologic Malignancy

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Solid Tumor | Hematologic Malignancy | Solid Tumor, Adult | Solid Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Hematologic Malignancies

United States
National Cancer Institute (NCI)

Completed

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States, Canada, New Zealand
Memorial Sloan Kettering Cancer Center

Terminated

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Non-Malignant Hematologic Disorders

United States
Weill Medical College of Cornell University

Active, not recruiting

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Hematologic Malignancy | Bone Marrow Transplant

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Dartmouth-Hitchcock Medical Center

Recruiting

Immune Profiling for Cancer Immunotherapy Response

Cancer | Hematologic Malignancy | Blood Cancer | Tumor, Solid

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
University of Rochester

Recruiting

An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies (APP SICP)

Hematologic Malignancies

United States
Kah Poh Loh

Withdrawn

A Multicomponent Technology Supported Care Delivery for Older Patients With Hematologic Malignancies (The M-Tech Study) (M-Tech)

Cancer

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Completed

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Hematologic Malignancy | Myeloproliferative Disorder

United States
Dartmouth-Hitchcock Medical Center

Completed

Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy

Hematologic Malignancies

United States
Dartmouth-Hitchcock Medical Center

Terminated

Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

Hematologic Malignancies

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Myeloid Diseases

United States
Memorial Sloan Kettering Cancer Center
Millennium: The Takeda Oncology Company

Completed

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Myeloid Hematologic Malignancy | Lymphoid Hematologic Malignancy

United States
Roswell Park Cancer Institute

Recruiting

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Hematopoietic and Lymphoid System Neoplasm

United States
Epizyme, Inc.

Withdrawn

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA)

Refractory Hematologic Malignancy | Relapsed Hematologic Malignancy

United States
Bristol-Myers Squibb
Exelixis

Terminated

A Study of BMS-863233 in Patients With Hematologic Cancer

Refractory Hematologic Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Genomic Profiling in Cancer Patients

Solid Tumors | Hematologic Cancers

United States
Smart Immune SAS

Recruiting

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Hematological Malignancies

United States
NYU Langone Health

Terminated

Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Hematopoietic Malignancies

United States
Surface Oncology

Completed

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Hematologic Cancers | Advanced Solid Cancers

United States, Canada
Infinity Pharmaceuticals, Inc.

Terminated

Dose Escalation of IPI-493 in Hematologic Malignancies

Hematologic Malignancies

United States
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Sight Diagnostics

Completed

Analytical and Clinical Performance Testing Plan

Hematology | Hematologic Test

United States
Essenlix Corporation

Completed

Clinical Evaluation of the iMOST-X1 Hematology Analyzer - Matrix Study

Hematologic Tests

United States
Weill Medical College of Cornell University

Active, not recruiting

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Hematologic Malignancies

United States
Memorial Sloan Kettering Cancer Center

Completed

Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

Leukemia

United States
Dartmouth-Hitchcock Medical Center

Completed

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Hematologic Malignancies

United States
Yale University
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

Hematologic Malignancies

United States
Northwestern University
National Cancer Institute (NCI); Hackensack Meridian Health; Lombardi Comprehensive...

Completed

Expressive Helping for Stem Cell Transplant Patients

Stem Cell Transplantation | Hematologic Malignancy

United States
Roswell Park Cancer Institute

Completed

Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients

Malignant Neoplasm | Parent | Hematologic and Lymphocytic Disorder | Guardian

United States

Clinical Trials on Dermatologic in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations